-
EP3303336
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3303336
| EP3303336 - IMIDAZO[1,2-B][1,2,4]TRIAZINE DERIVATIVES AS ANTIPARASITIC AGENTS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 10.07.2020 Database last updated on 01.01.2025 | |
| Former | Grant of patent is intended Status updated on 23.09.2019 | ||
| Former | Examination is in progress Status updated on 18.01.2019 | ||
| Former | Request for examination was made Status updated on 09.03.2018 | ||
| Former | The international publication has been made Status updated on 09.12.2016 | Most recent event Tooltip | 10.07.2020 | Application deemed to be withdrawn | published on 12.08.2020 [2020/33] | Applicant(s) | For all designated states GlaxoSmithKline Intellectual Property Development Limited 980 Great West Road Brentford Middlesex TW8 9GS / GB | For all designated states The University of Dundee 11 Perth Road Dundee DD1 4HN / GB | [2018/15] | Inventor(s) | 01 /
BRAND, Stephen The University of Dundee Drug Discovery Unit Dundee Tayside DD1 5EH / GB | 02 /
GAZA, Elisabet Viayna The University of Dundee Drug Discovery Unit Dundee Tayside DD1 5EH / GB | 03 /
GILBERT, Ian The University of Dundee Drug Discovery Unit Dundee Tayside DD1 5EH / GB | 04 /
KO, Eun Jung The University of Dundee Drug Discovery Unit Dundee Tayside DD1 5EH / GB | 05 /
THOMAS, Michael George The University of Dundee Drug Discovery Unit Dundee Tayside DD1 5EH / GB | 06 /
MARCO MARTIN, Maria GlaxoSmithKline Tres Cantos 28760 Madrid / ES | 07 /
MILES, Timothy James GlaxoSmithKline Tres Cantos 28760 Madrid / ES | 08 /
SANDBERG, Lars, Henrik University of Dundee Drug Discovery Unit Dundee Tayside DD1 5EH / GB | [2018/15] | Representative(s) | Sardharwala, Fatema Elyasali GSK Legal & Compliance - Global Patents 79 New Oxford Street London WC1A 1DG / GB | [N/P] |
| Former [2018/15] | Sardharwala, Fatema Elyasali GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road Brentford, Middlesex TW8 9GS / GB | Application number, filing date | 16724912.7 | 26.05.2016 | [2018/15] | WO2016EP61887 | Priority number, date | EP20150382283 | 29.05.2015 Original published format: EP 15382283 | [2018/15] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2016193111 | Date: | 08.12.2016 | Language: | EN | [2016/49] | Type: | A1 Application with search report | No.: | EP3303336 | Date: | 11.04.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 08.12.2016 takes the place of the publication of the European patent application. | [2018/15] | Search report(s) | International search report - published on: | EP | 08.12.2016 | Classification | IPC: | C07D487/04, A61K31/53, A61K31/5377, A61K31/553, A61P33/02 | [2018/15] | CPC: |
C07D487/04 (EP,CN,US);
A61K31/53 (EP,US);
A61K31/5377 (EP,US);
A61K45/06 (US);
A61P33/02 (EP,US);
Y02A50/30 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/15] | Extension states | BA | 29.11.2017 | ME | 29.11.2017 | Title | German: | IMIDAZO[1,2-B][1,2,4]TRIAZIN-DERIVATE ALS ANTIPARASITIKA | [2019/41] | English: | IMIDAZO[1,2-B][1,2,4]TRIAZINE DERIVATIVES AS ANTIPARASITIC AGENTS | [2018/15] | French: | DÉRIVÉS D'IMIDAZO[1,2-B][1,2,4]TRIAZINE COMME AGENTS ANTIPARASITAIRES | [2019/41] |
| Former [2018/15] | IMIDAZO[1,2-B][1,2,4]TRIAZIN-DERIVATE ALS ANTIPARASITÄRE MITTEL | ||
| Former [2018/15] | DÉRIVÉS D'IMIDAZO[1,2-B][1,2,4]TRIAZINE UTILISÉS COMME AGENTS ANTIPARASITAIRES | Entry into regional phase | 29.11.2017 | National basic fee paid | 29.11.2017 | Designation fee(s) paid | 29.11.2017 | Examination fee paid | Examination procedure | 29.11.2017 | Amendment by applicant (claims and/or description) | 29.11.2017 | Examination requested [2018/15] | 29.11.2017 | Date on which the examining division has become responsible | 22.01.2019 | Despatch of a communication from the examining division (Time limit: M04) | 28.05.2019 | Reply to a communication from the examining division | 24.09.2019 | Communication of intention to grant the patent | 05.02.2020 | Application deemed to be withdrawn, date of legal effect [2020/33] | 12.03.2020 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2020/33] | Fees paid | Renewal fee | 07.05.2018 | Renewal fee patent year 03 | 08.05.2019 | Renewal fee patent year 04 | 30.03.2020 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [AD]US2014275119 (LIANG FANG [US], et al) [AD] 1-22 * compounds of the examples; page 1, paragraph 3; claims 1,15,16; table I *; | [AD]US2014275013 (CHATTERJEE ARNAB KUMAR [US], et al) [AD] 1-22 * compounds of the examples; page 1, paragraph 3; claims 1,18,19; table I *; | [ADP]WO2015095477 (IRM LLC [US], et al) [ADP] 1-22* compounds of the examples; page 1, paragraph 1; claims 1,14,15; table 1 * | by applicant | US2014275119 | US2014275013 | WO2014151784 | WO2014151630 | WO2015095477 | US2015175613 | - ALVAR J. ET AL., "Leishmaniasis Worldwide and Global Estimates of Its Incidence", PLOS ONE, (2012), vol. 7, no. 5, page E35671 | - SEIFERT K., "Structures, Targets and Recent Approaches in Anti-Leishmanial Drug Discovery and Development", OPEN MED CHEM J., (2011), vol. 5, pages 31 - 39 | - BERMAN JD; BADARO R; THAKUR CP; WASUNNA KM; BEHBEHANI K ET AL., "Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries", BULL WORLD HEALTH ORGAN, (1998), vol. 76, pages 25 - 32 | - HAILU A; MUSA A; WASUNNA M; BALASEGARAM M; YIFRU S ET AL., "Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial", PLOS NEGL TROP DIS, (2010), vol. 4, no. 10, page E709 | - BERGE ET AL., J. PHARM. SCI., (1977), vol. 66, pages 1 - 19 | - DRUGS OF TODAY, (1983), vol. 19, no. 9, pages 499 - 538 | - Topics in Chemistry, pages 306 - 316 | - E.W. MARTIN, Remington's Pharmaceutical Sciences | - DE RYCKER ET AL., ANTIMICROB AGENTS CHEMOTHER., (201307), vol. 57, no. 7, pages 2913 - 22 | - RAZ B.; ITEN M.; GRETHER-BUHLER Y.; KAMINSKI R.; BRUN R., "The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T. b. rhodesiense and T. b. gambiense) in vitro", ACTA TROP., (1997), vol. 68, pages 139 - 147 | - HIRUMI H.; HIRUMI K., "Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum-protein without feeder cell-layers", J. PARASITOL., (1989), vol. 75, pages 985 - 989 |